FDA Approves PleximmuneTM for Personalized Prediction of Transplant Rejection in Children
Today the FDA announced approval of PleximmuneTM, a blood test from the Pittsburgh-based biotech company Plexision. This test predicts acute cellular rejection of transplanted livers and intestines in children. PleximmuneTM is a first-in-class test to determine a personalized rejection-risk index... - September 11, 2014
Press Releases 1 - 1 of 1